Neurocrine Biosciences Shares Up 7% Despite Q4 Miss; Guidance is Optimistic
<p><a href='https://financialmodelingprep.com/financial-summary/NBIX'>Neurocrine Biosciences, Inc. (NASDAQ:NBIX) </a>shares closed more than 7% higher on Friday, despite the company’s reported Q4 miss, with EPS coming in at $0.04, significantly below the  Street estimate of $0.58. Revenue was $303.5 million, compared to the Street estimate of $320 million.</p>
<p>Analysts at Oppenheimer view the company’s guidance as optimistic, stating that they are encouraged by management's decision to provide first-time 2022 Ingrezza sales guidance, which is viewed as a signal of increased confidence and transparency in the business model. The company expects $1.25-$1.35 billion of Ingrezza net sales in 2022 representing 20% growth at the mid-point driven entirely by volume as net price/script of around $5,400 is expected to remain relatively constant. </p>

NASDAQ:NBIX